Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | EVP, Chief Financial Officer | July 30, 2026 | August 03, 2026 |
| TerrAscend Corp.TSNDF · Entity 6184 | Director | June 24, 2025 | June 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERON THERAPEUTICS, INC. /DE/
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 281,899 |
Ending reported balance
After 2026-07-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-30 · Exercise / conversion · Acquired 13,535 · Balance 277,381 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2026-07-30 · Tax withholding · Disposed 3,850 · Balance 273,531 Row 3 · 2026-07-31 · Exercise / conversion · Acquired 11,694 · Balance 285,225 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 4 · 2026-07-31 · Tax withholding · Disposed 3,326 · Balance 281,899 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 189,492 |
Reported balance
After 2026-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-30 · Exercise / conversion · Disposed 13,535 · Balance 189,492 F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 116,944 |
Reported balance
After 2026-07-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-31 · Exercise / conversion · Disposed 11,694 · Balance 116,944 F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.
F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
TerrAscend Corp.
Report date June 24, 2025 · Filed June 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 657,930 |
Reported balance
After 2025-06-24 transaction · row 1
1 source rowRow 1 · 2025-06-24 · Grant · Acquired 433,653 · Balance 657,930 F1: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2024 Filed Jun 17, 2024 18:21 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-074168 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 19, 2024 Filed Apr 19, 2024 21:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionRestricted Stock Units · Derivative | 3,874 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-046134 · ownership.xml · derivative · entry 3 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,115 Underlying: Common Stock · 3,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| April 19, 2024 Filed Apr 19, 2024 21:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Tax withholdingCommon Stock | 1,122 | $2.64 | $2,962.08 |
DisclosureSEC source: 0000950170-24-046134 · ownership.xml · nonDerivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,752 Read SEC document |
| April 19, 2024 Filed Apr 19, 2024 21:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 3,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-046134 · ownership.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 19, 2024 Filed Jan 20, 2024 02:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantRestricted Stock Units · Derivative | 61,989 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001975 · doc4.xml · derivative · entry 2 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,989 Underlying: Common Stock · 61,989 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document |
| January 19, 2024 Filed Jan 20, 2024 02:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 371,935 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-24-001975 · doc4.xml · derivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,935 Underlying: Common Stock · 371,935 shares Expires 2034-01-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (01/19/2024). Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 17:36 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | PurchaseCommon Stock | 85,000 | $0.89 | $75,599.00 |
DisclosureSEC source: 0001209191-23-055663 · doc4.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · price: The range of purchase prices paid was $0.8708 to $0.9201. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased at each separate price. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 18:44 UTC | TerrAscend Corp. TRSSF · Entity 6184 | GrantCommon Stock | 132,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039628 · doc4.xml · nonDerivative · entry 1 Duarte Ira · CIK 0001488864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,647 F1 · shares: These shares represent an annual grant of restricted share units ("RSUs") for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2023, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.